Ron Rosenstraus
@Eversept Partners, Lp
Latest period2024 - Q3ReportedManaged Assets$1.46BTotal holdings67
Assets growth rate-0.03%Assets growth rate (2-Q avg)-1.3%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Eversept Partners, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 67 positions.
Assets under management
The assets under management (AUM) of Eversept Partners, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.46B in assets, with a quarterly growth rate of -0.03% and a 2-quarter average growth rate of -1.3%. The portfolio is managed by Ron Rosenstraus, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MLTXMoonlake Immunotherapeutics
| 0% | $3.148M 71,596 shares@ $43.97 avg price | Exited |
GHGuardant Health Inc
| 0% | $2.87M 99,377 shares@ $28.89 avg price | Exited |
IMVTImmunovant Inc
| 0% | $2.453M 92,909 shares@ $26.41 avg price | Exited |
TERNTerns Pharmaceuticals Inc
| 0% | $1.949M 286,266 shares@ $6.81 avg price | Exited |
FULCFulcrum Therapeutics Inc
| 0% | $948,383 152,965 shares@ $6.2 avg price | Exited |
GTHXG1 Therapeutics Inc
| 0% | $455,916 199,963 shares@ $2.29 avg price | Exited |
MCRBSeres Therapeutics Inc
| 0% | $302,699 418,208 shares@ $0.73 avg price | Exited |